Venous and arterial thromboembolic risk of Janus kinase inhibitors: a systematic review with meta-analysis
Pooled result · Thromboembolic eventsResult — go to the resultOdds ratio 0.82 95% CI 0.43–1.56Authors' conclusion
JAKi do not increase thromboembolic risk compared with placebo in IMID patients enrolled in selected RCTs.
Study context
- Population
- Patients with immune-mediated inflammatory diseases (IMIDs) in randomized controlled trials (RCTs) of JAKi identified in MEDLINE and EMBASE until October 2021RCTs on JAKi in IMIDs
- Participants
- 19,443 vs 6,354
- Comparison
- JAKi vs control
- JAKin = 19,443
- Controln = 6,354reference
- Outcome
- Venous and arterial thromboembolic events
Methodological detailsbeta-binomial model, Cochrane risk of bias assessment
- Beta-binomial model
- Cochrane risk of bias assessment
Pooled result
Thromboembolic events · mean follow-up of 16.8 weeks
Odds ratio
0.82
95% CI 0.43–1.56
Events by group
JAKivs Control
OR 0.82 (95% CI 0.43–1.56)
As reported in the abstract
Further pooled results
- No statistically different results in subanalyses for each investigated IMID, drug and dosage
Original publication
Venous and arterial thromboembolic risk of Janus kinase inhibitors: a systematic review with meta-analysis. Rheumatology (Oxford). Published 18 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →